Deucravacitinib

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the TYK2 inhibitor deucravacitinib from the Maui Derm 2024 meeting, examining its use as a treatment for psoriasis.

The efficacy of deucravacitinib was superior to placebo and apremilast in treating scalp psoriasis, according to pooled results of two studies.

Three-year data from the POETYK PSO long-term extension trial of Sotyktu showed consistent efficacy and safety for the treatment of adults with moderate to severe plaque psoriasis, Bristol Myers Squibb announced in a press release.

M. Elaine Husni, MD, MPH, spoke with Healio about treatment and management options in psoriatic arthritis, including lifestyle changes. “We now have really embraced the concept of wellness strategies,” said Husni, vice chair of rheumatology and director of the Arthritis and Musculoskeletal Center and staff physician in the Orthopedic and Rheumatologic Institute at Cleveland Clinic, and assistant professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

M. Elaine Husni, MD, MPH, spoke with Healio about treatment and management options in psoriatic arthritis, including lifestyle changes. “We now have really embraced the concept of wellness strategies,” said Husni, vice chair of rheumatology and director of the Arthritis and Musculoskeletal Center and staff physician in the Orthopedic and Rheumatologic Institute at Cleveland Clinic, and assistant professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

The European Commission has approved Sotyktu in the European Union for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, Bristol Myers Squibb announced in a press release.

The European Medicines Agency has recommended the approval of Sotyktu for the treatment of adults with moderate to severe plaque psoriasis, Bristol Myers Squibb announced in a press release.

PHILADELPHIA — Phase 2 findings for the tyrosine kinase 2 inhibitor deucravacitinib yielded encouraging results through 48 weeks in patients with systemic lupus erythematosus, according to data presented at ACR Convergence 2022.

Deucravacitinib demonstrated superiority compared with placebo and apremilast in the treatment of adults with moderate to severe plaque psoriasis, according to findings from a phase 3 trial.

MILAN — Deucravacitinib demonstrated efficacy and safety in treating patients with systemic lupus erythematosus and sustained improvement up to 48 weeks.